Technical analysis of Aspire Biopharma Holdings, Inc. (ASBP): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management.
Price Performance
| 1 month | +12.30% |
| 3 months | +30.40% |
| Year-to-date | -94.58% |
| 1 year | -98.41% |
| 3 years | -99.94% |
52-Week Range
| 52-week High | $562.80 |
| 52-week Low | $3.31 |
| Avg Volume (90d) | 299K |
Technical Indicators
| SMA 50 | $7.57 |
| SMA 200 | $35.39 |
| 30-day Volatility (annualised) | 63.8% |
| Price vs SMA 50 | +13.4% |
| Price vs SMA 200 | -75.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $459.60 | |
| 2025-11 | $127.20 | -72.3% |
| 2025-12 | $158.40 | +24.5% |
| 2026-01 | $63.90 | -59.7% |
| 2026-02 | $41.70 | -34.7% |
| 2026-03 | $30.90 | -25.9% |
| 2026-04 | $6.64 | -78.5% |
| 2026-05 | $5.49 | -17.3% |
| 2026-06 | $5.34 | -2.7% |
| 2026-07 | $6.52 | +22.1% |
| 2026-08 | $8.98 | +37.7% |
| 2026-09 | $8.58 | -4.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $8.58 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -37.44 |
| EV / EBITDA | -20.93 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.22 |
| Current Ratio | 0.17 |